PT  - JOURNAL ARTICLE
AU  - Klann Meng, Jeffrey G
AU  - Strasser, Zachary H
AU  - Hutch, Meghan R
AU  - Kennedy, Chris J
AU  - Marwaha, Jayson S
AU  - Morris, Michele
AU  - Samayamuthu, Malarkodi Jebathilagam
AU  - Pfaff, Ashley C
AU  - Estiri, Hossein
AU  - South, Andrew M
AU  - Weber, Griffin M
AU  - Yuan, William
AU  - Avillach, Paul
AU  - Wagholikar, Kavishwar B
AU  - Luo, Yuan
AU  - ,
AU  - Omenn, Gilbert S
AU  - Visweswaran, Shyam
AU  - Holmes, John H
AU  - Xia, Zongqi
AU  - Brat, Gabriel A
AU  - Murphy, Shawn N
TI  - Distinguishing Admissions Specifically for COVID-19 from Incidental SARS-CoV-2 Admissions: A National EHR Research Consortium Study
AID  - 10.1101/2022.02.10.22270728
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.10.22270728
4099  - http://medrxiv.org/content/early/2022/02/15/2022.02.10.22270728.short
4100  - http://medrxiv.org/content/early/2022/02/15/2022.02.10.22270728.full
AB  - Admissions are generally classified as COVID-19 hospitalizations if the patient has a positive SARS-CoV-2 polymerase chain reaction (PCR) test. However, because 35% of SARS-CoV-2 infections are asymptomatic, patients admitted for unrelated indications with an incidentally positive test could be misclassified as a COVID-19 hospitalization. EHR-based studies have been unable to distinguish between a hospitalization specifically for COVID-19 versus an incidental SARS-CoV-2 hospitalization. From a retrospective EHR-based cohort in four US healthcare systems, a random sample of 1,123 SARS-CoV-2 PCR-positive patients hospitalized between 3/2020–8/2021 was manually chart-reviewed and classified as admitted-with-COVID-19 (incidental) vs. specifically admitted for COVID-19 (for-COVID-19). EHR-based phenotyped feature sets filtered out incidental admissions, which occurred in 26%. The top site-specific feature sets had 79-99% specificity with 62-75% sensitivity, while the best performing across-site feature set had 71-94% specificity with 69-81% sensitivity. A large proportion of SARS-CoV-2 PCR-positive admissions were incidental. Straightforward EHR-based phenotypes differentiated admissions, which is important to assure accurate public health reporting and research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJSM is supported by NIH/National Library of Medicine (NLM) T15LM007092. MM is supported by National Institutes of Health (NIH)/ National Center for Advancing Translational Sciences (NCATS) UL1TR001857. AMS is supported by NIH/ National Heart, Lung, and Blood Institute (NHLBI) K23HL148394 and L40HL148910, and NIH/NCATS UL1TR001420. GMW is supported by NIH/NCATS UL1TR002541, NIH/NCATS UL1TR000005, NIH/ NLM R01LM013345, and NIH/ National Human Genome Research Institute (NHGRI) 3U01HG008685-05S2. WY is supported by NIH T32HD040128. KBW is supported by NIH/NHLBI R01 HL151643-01. YL is supported by NIH/NCATS U01TR003528, and NLM 1R01LM013337. GSO is supported by NIH U24CA210867 and P30ES017885. SV is supported by NCATS UL1TR001857. JHH is supported by NCATS UL1-TR001878. ZX is supported by National Institute of Neurological Disorders and Stroke (NINDS) R01NS098023 and NINDS R01NS124882. SNM is supported by NCATS 5UL1TR001857-05 and NHGRI 5R01HG009174-04.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB Approval was obtained at Beth Israel Deaconess Medical Center, Massachusetts General Brigham, Northwestern University, and University of Pittsburgh.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe electronic health record datasets analyzed during the current study cannot be made publicly available due to regulations for protecting patient privacy and confidentiality. These regulations also prevent the data from being made available upon request from the authors. Any questions about the dataset can be directed to the corresponding author. https://github.com/jklann/jgk-i2b2tools/tree/master/4CE_utils